On a constant currency basis, it increased by 26 per cent year-on-year to around $1.62 billion led by improvement in volumes and new product launches.
The company has received final approval for six ANDAs (abbreviated new drug application) and launched four products in the fourth quarter of last fiscal.
For the full year, it has received approval for 22 ANDAs and launched 34 products across oral, injectable and OTC segments, Govindarajan said. Replying to a query, he said the drugmaker is planning to spend $150 to $200 million on capex in the current year.
Aurobindo spent Rs 958 crore towards research and development in FY 20 which was 4.1 per cent of its total revenues.
Govindarajan said the R&D spend would be 5.5 per cent of the revenues for the current year.